

Kidney Cancer Association

Announcing the Advanced Discovery Award (ADA)

The Kidney Cancer Association announces \$1 million in new research funding with the Advanced Discovery Award. Two \$500,000 awards will be distributed in Fall 2019 to a collaborative team with the goal to significantly decrease mortality rates amongst kidney cancer patients.

Focus: The purpose of these two research awards is to promote the collaboration between a clinician and a translational researcher to propose novel research that will lead to a significant advance in the treatment of patients with kidney cancer. This may include biomarker development, development of novel therapeutic targets, correlative studies associated with ongoing or completed clinical trials, or assays that promote the early detection of kidney cancer. Any and all proposals will be evaluated through the Letter of Intent (LOI) Process.

All application materials will be submitted electronically in PDF format, in English, to grants@kidneycancer.org.

All questions regarding the grant application process should be submitted to grants@kidneycancer.org.

Applicant: Collaboration between a minimum of one clinician (M. D., D. O., or equivalent) and one translational researcher (Ph. D., M. D., D. O.) with at least one team member having an academic rank of Associate Professor or higher. The collaboration can be intra or inter institutional.

Funding: \$500,000 over two years. Funding will be distributed in \$250,000 allotments for years 1 and 2, with the second allotment contingent on the successful submission of a progress report highlighting the accomplishments of the first year of work. The funding is to be used solely for research costs, with a maximum of 5% utilized for institutional indirect costs if necessary. The funding cannot be used for the investigator's salary support or things not directly related to the proposed research (travel, society memberships, etc.). The research award can be used to support the salaries of research personnel directly involved in the conduct of the research proposed.

Timeline for the Application and Granting Process:

| | |
|--------------------|--|
| April 17, 2019: | Call for Letters of Intent |
| May 20, 2019: | Final Day to submit Letters of Intent |
| June 10, 2019: | Final Day that Meritorious LOI Proposals will be notified to proceed with preparation and submission of a full proposal for evaluation |
| August 5, 2019: | Final Day to submit Full Proposal for academic review |
| September 9, 2019: | The two winning research teams will be notified and announced publicly |
| October 7, 2019: | Initial awards of \$250,000 distributed to award winners |
| October 7, 2020: | Progress Report on 1 st year of research progress due. If deemed meritorious, the second allotment of \$250,000 will be dispersed |
| October 7, 2021: | Final Progress Report Due |

Reviewers: An independent panel of reviewers who are recognized experts in the field will be assembled to conduct a blinded scored review of the letters of intent and the final proposals based on published NIH guidelines. Members with a conflict of interest on a given proposal will recuse themselves from the deliberation.

Letters of Intent: Applicants will submit a two page, single spaced, Arial 11 font proposal in PDF format for review. The proposal should highlight the background, relevance, and the potential impact of the research proposed. Hypotheses or specific aims to be tested should be clearly stated and a brief review of the methodology should be included. A statement of how this research will advance the field regarding the potential impact on patient care must be included. Relevant references should also be cited in the document.

Accompanying Documentation: Accompanying the Letter of Intent should be the contact information and biosketches of the collaborative researchers as well as a one paragraph personal statement from each of the researchers regarding their background and commitment to research in the field of kidney cancer. Relevant IRB approved protocols for use of human or animal specimens in the proposed research should also be included. Supporting documentation from a pharmaceutical company should be included if a drug is proposed in the research plan. Finally, a letter of support from

each applicant's department or division chairman should accompany the letter of intent.

Applicants will be notified by email as to the status of their letter of intent by June 10, 2019.

Full Proposals:

Meritorious applicants selected to submit a full proposal will submit a 6 page, single spaced, Arial font 11 document in PDF format. All relevant graphs, tables, and figures must be included within the 6 pages. The document should elaborate on the background and work done to date. Specific Aims must be clearly stated and the methodology to accomplish the specific aims detailed, including alternative methods should the primary plan go awry. The potential impact on the care of patients with kidney cancer must be stated. Timelines and actionable goals of the research plan should be highlighted. Relevant literature should be cited. A budget and a justification for said budget must be included. Applicants should indicate whether or not their research proposal is under consideration by other granting mechanisms.

Award winners will be notified by September 9, 2019 and initial funds will be dispersed by October 7, 2019.

Award winners must agree to present their research at the annual International Kidney Cancer Symposium held in the United States, after the completion of their second year of research.